The Multiple Myeloma Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Multiple Myeloma Channel on VJHemOnc receives independent medical education support from Takeda, BMS, Amgen and Legend Biotech. These supporters have no influence over the production of the content.

Latest Videos The Myeloma Sessions Conferences Topics Podcasts Features Expert Editorial Board

Welcome to The Multiple Myeloma Channel

In association with our world-leading Editorial Board, VJHemOnc brings you the latest updates in multiple myeloma, directly from the experts. As well as video interviews, you can listen to our podcasts, dive into a roundtable discussion and e-learning, or read our feature articles.

The Myeloma Channel brings you the latest advances in therapy, including monoclonal antibodies, CAR-T cells, bispecific antibodies, as well as up-to-date data and guidance on optimizing treatment combinations, sequencing and managing difficult-to-treat patient groups. The Myeloma Channel also delves into the latest research on the understanding of precursor state progression, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma to active disease, the tumor microenvironment, and more.

Conferences

COMy 2023
EBMT 2023
BSH 2023
Tandem Meetings 2023
CAR-T Meeting 2023
ASH 2022
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:02
Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat • 12 May 2023
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:49
Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials
Luciano Costa • 13 May 2023
View All Videos
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023
2:00
Utilizing cytokine profiles at baseline to predict cytopenia after treatment with ide-cel
Razan Mohty • 25 Apr 2023
1:03
Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai • 25 Apr 2023
5:31
Cellular immunotherapy highlights from EBMT 2023
Mohamad Mohty • 25 Apr 2023
View All Videos
2:40
OPTIMAL: bortezomib-based therapy vs thalidomide-based therapy in myeloma with renal failure
Karthik Ramasamy • 25 Apr 2023
2:31
The value of BCMA-targeting therapy in multiple myeloma: current applications and future outlooks
Karthik Ramasamy • 25 Apr 2023
2:36
Updated analysis of the MAIA trial: long-term safety and efficacy data
Supratik Basu • 24 Apr 2023
1:38
Correlation between extreme BMI and survival in patients with multiple myeloma
Urvi Shah • 24 Apr 2023
View All Videos
15:54
Characteristics and clinical outcomes of patients with NDMM undergoing upfront autoSCT
Laurent Garderet • 13 Apr 2023
2:22
The benefit of autologous transplantation in the era of novel agents in multiple myeloma
Muzaffar Qazilbash • 24 Feb 2023
2:10
Phase II study of EPd maintenance after second autologous transplant for multiple myeloma
Michael Slade • 15 Feb 2023
1:27
The use of salvage second autologous transplant in the age of novel therapies for multiple myeloma
Michael Slade • 15 Feb 2023
View All Videos
0:55
The main aims of Myeloma Canada & the value of patient organizations
Martine Elias • 10 Feb 2023
1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
2:03
CAR-T therapy in myeloma: moving into earlier lines and treating patients with unmet medical needs
Paula Rodríguez-Otero • 16 Feb 2023
0:53
The promise of CAR-T cells for patients with triple-class exposed myeloma
Hermann Einsele • 10 Feb 2023
View All Videos
2:54
Using whole genome sequencing to track early events in multiple myeloma
Francesco Maura • 12 Dec 2022
2:29
Myeloma highlights at ASH 2022: BiTEs, CAR-T therapy, novel targets, and more
Noopur Raje • 11 Dec 2022
2:47
iStopMM analysis results: autoimmune diseases are not associated with MGUS
Sigurdur Kristinsson • 12 Dec 2022
1:25
Adverse events associated with the use of carfilzomib
Meral Beksac • 12 Dec 2022
View All Videos

Topics

MRD
Transplant
CAR-T & Cellular Therapy
Real-World Data
Trial Updates
Immuno-Oncology
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:25
Using MRD to improve prognostication during the maintenance phase of myeloma treatment
Bruno Paiva • 12 May 2023
View All Videos
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:57
Strategies to optimize CAR-T therapy in myeloma: bringing CAR-T into earlier lines
Michel Delforge • 13 May 2023
2:36
Updated analysis of the MAIA trial: long-term safety and efficacy data
Supratik Basu • 24 Apr 2023
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:02
Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat • 12 May 2023
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:49
Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials
Luciano Costa • 13 May 2023
View All Videos
1:54
Using real-world data to optimize treatment in patients with multiple myeloma
Claudio Cerchione • 12 May 2023
1:38
Correlation between extreme BMI and survival in patients with multiple myeloma
Urvi Shah • 24 Apr 2023
2:37
Dietary and microbiome evidence in myeloma & other plasma cell disorders
Urvi Shah • 24 Apr 2023
15:54
Characteristics and clinical outcomes of patients with NDMM undergoing upfront autoSCT
Laurent Garderet • 13 Apr 2023
View All Videos
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:49
Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials
Luciano Costa • 13 May 2023
2:57
Strategies to optimize CAR-T therapy in myeloma: bringing CAR-T into earlier lines
Michel Delforge • 13 May 2023
2:40
OPTIMAL: bortezomib-based therapy vs thalidomide-based therapy in myeloma with renal failure
Karthik Ramasamy • 25 Apr 2023
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:02
Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat • 12 May 2023
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:49
Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials
Luciano Costa • 13 May 2023
View All Videos

The Multiple Myeloma Channel on VJHemOnc receives independent medical education support from Takeda, BMS, Amgen and Legend Biotech.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Multiple Myeloma Channel, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals